Free Webinar for Biotech, Pharma, and Global Health Innovators

Bringing a vaccine asset into clinical testing is a defining and complex milestone. From selecting the right country and regulatory path to optimizing trial design with epidemiological data, the decisions you make early can make or break your development timeline.

In this 60-minute expert-led Webinar, learn exactly how Europe, including Belgium, can accelerate your asset’s clinical journey.

How to run early-phase vaccine trials in Europe Webinar: What You’ll Learn

• How to use epidemiological data to sharpen trial design and meet regulatory expectations
• Why Belgium offers a strategic advantage for early-phase and human vaccine trials
• When and how to apply alternative development models like adaptive design
• How clinical endpoints likely predicting efficacy have been used to support vaccine licensure
• Common pitfalls in early vaccine development, and how to avoid them
• How P95 supports biotech and global health teams with flexible trial delivery models

Webinar Details

• Date: Monday, July 28, 2025
• Time: 15:30 CET
• Location: Online via Xtalks
• Includes: Live Q&A session with all speakers

Meet The Speakers

Laurence De Moerlooze serves as Chief Medical Officer at P95, drawing on more than two decades of experience in vaccine R&D and clinical leadership. She began her career at GSK Biologicals, where over 15 years she played a central role in regulatory, medical, and strategic functions. Contributing to the development of several high-impact vaccines, including one targeting HPV. Her work later expanded at Takeda, where she led global vaccine programs focused on Zika and Norovirus. Before joining P95, Laurence spent four years as Executive Vice President and CMO at Bavarian Nordic, guiding the company’s clinical pipeline across infectious disease areas. She holds a PhD in Virology from the University of Liège and completed postdoctoral research in Canada, the UK, and Belgium.

Prof. Dr. Pierre Van Damme, a prominent figure in vaccinology, obtained his MD and PhD from the University of Antwerp and has been active in vaccine research for over 35 years. He has been a full professor at the University of Antwerp since 2000 and is the founder and director of the Centre for the Evaluation of Vaccination (CEV), a WHO Collaborating Centre. Under his leadership, the CEV has conducted over 500 vaccine trials, including a notable oral polio vaccine trial for the Gates Foundation. In 2022, he launched Vaccinopolis for advanced vaccine trials. He has authored over 550 peer-reviewed papers and received several awards.

Kaatje Bollaerts is the Epidemiology Business Head at P95, where she oversees the design, execution, and strategy of global epidemiological research focused on vaccines and infectious diseases. With over 18 years of experience and a PhD in Biostatistics from Hasselt University, she has led major public-private initiatives such as ADVANCE, DRIVE, VITAL, COVIDRIVE, and id.DRIVE. Before joining P95 in 2013, she held research roles at Sciensano and KU Leuven, contributing to national public health efforts. Kaatje is widely recognized for her scientific leadership, collaborative approach, and commitment to translating data into meaningful public health insights.

Who Should Attend

• Biotech founders, clinical leads, and regulatory strategists preparing for first-in-human trials
• Sponsors and NGOs advancing vaccine assets toward proof-of-concept
• Pharma and public-private partnerships planning early-phase studies in Europe
• Clinical operations leaders evaluating trial locations and execution partners
• Development teams looking to reduce risk, timelines, and cost while maintaining quality

Register now and reserve your seat at the How to Run Early-Phase Vaccine Trials in Europe Webinar with P95 & Vaccinopolis.